Kineta partners with Samsung Biologics on novel I-O option
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics (KRX: 207940.KS) has inked a strategic partnership agreement with Seattle, USA-based biotech Kineta.
Kineta is working on novel immunotherapies in oncology and is building up to an Investigational New Drug (IND) filing for KVA12.1, a novel anti-VISTA antibody in development for the treatment of solid tumors.
According to the agreement, Samsung Biologics will provide end-to-end CDMO services from cell line development to clinical drug substance and drug product manufacturing.
Kineta has identified VISTA as a key driver of the immunosuppressive tumor microenvironment (TME) and a critical myeloid cell immune-checkpoint.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze